<DOC>
	<DOCNO>NCT02213744</DOCNO>
	<brief_summary>This study open label , randomize , multicenter trial MM-302 plus trastuzumab . The trial design demonstrate whether MM-302 plus trastuzumab effective chemotherapy physician 's choice ( CPC ) plus trastuzumab locally advanced/metastatic HER2-positive breast cancer patient . Patients may previously treat anthracycline set . Patients must receive prior treatment trastuzumab setting , either progressed intolerant ado-trastuzumab emtansine metastatic locally advanced setting , either progress intolerant pertuzumab metastatic locally advanced set disease recurrence within 12 month pertuzumab treatment neoadjuvant adjuvant setting .</brief_summary>
	<brief_title>MM-302 Plus Trastuzumab v . Chemotherapy Physician 's Choice Plus Trastuzumab HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Patients must histologically cytologically confirm invasive cancer breast Patients must document locally advanced/metastatic disease , define investigator , amenable resection curative intent . Patients must HER2positive breast cancer define ASCO/CAP 2013 guideline confirm Sponsordesignated central laboratory Patients must progress , intolerant pertuzumab LABC/MBC set disease recurrence within 12 month pertuzumab treatment neoadjuvant adjuvant setting . Patients must progress , intolerant adotrastuzumab emtansine LABC/MBC setting Patients must previously treat trastuzumab set ( may previously administer without pertuzumab ) ECOG Performance Status 0 1 Patients previously treat doxorubicin , liposomal doxorubicin , epirubicin , mitoxantrone , anthracycline derivative Subjects central nervous system ( CNS ) metastases , unless treat stable without symptom 4 week completion treatment must steroids least 4 week prior enrollment Patients class New York Heart Association ( NYHA ) CHF heart failure preserve ejection fraction ( HFPEF ) Patients history know coronary artery disease myocardial infarction within last 12 month Patients known history serious cardiac arrhythmia require treatment ( exception : control atrial fibrillation , paroxysmal supraventricular tachycardia ) Patients previously discontinue trastuzumab due unacceptable cardiac toxicity Patients history LVEF decline 50 % prior trastuzumab/lapatinib HER2 direct therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>HER2-positive</keyword>
	<keyword>HER2+</keyword>
	<keyword>HER2</keyword>
	<keyword>Locally Advanced Breast Cancer</keyword>
	<keyword>Metastatic Breast Cancer</keyword>
	<keyword>trastuzumab</keyword>
	<keyword>Herceptin</keyword>
	<keyword>pertuzumab</keyword>
	<keyword>ado-trastuzumab emtansine</keyword>
	<keyword>TDM-1</keyword>
	<keyword>Perjeta</keyword>
	<keyword>Kadcyla</keyword>
</DOC>